Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

(2019) Begoña Pineda et al.   Clinical Epigenetics

Integrated analysis of genome-wide gene expression and DNA methylation microarray of diffuse large B-cell lymphoma with TET mutations

(2017) Pengfei Liu et al.   Molecular Medicine Reports

Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

(2015) Clare Stirzaker et al.   Nature Communications

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY